Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Cellular Biomedicine Accepts $383 Million Management-led Privatization Offer

publication date: Aug 12, 2020

Cellular Biomedicine, a biopharma headquartered in Maryland with operations in Shanghai, signed a definite $383 million go-private merger agreement with a company formed by management and an investment syndicate. CBMG is developing immunotherapies for cancer and stem cell therapies for degenerative diseases. The agreement was set at $19.75 per share, slightly higher than the original $19.50 per share offered last fall and 31% above the company's average price over the last 30 days. More details....

Stock Symbol: (NSDQ: CBMG)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here